KRAS and non-small cell lung carcinoma: A phase II trial of subcutaneous bortezomib in patients with stage IIIB/IV or recurrent/medically inoperable NSCLC with documented KRAS G12D mutation was initiated by Riely et al. in 2013, with 16 patients enrolled.